TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number and Severity of Participants With Adverse Events (AEs) and Serious AEs (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Severity (by Worst Grade) of Participants With Adverse Events (AEs) and Serious AEs (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number and Severity of Participants With Drug-related Adverse Events (AEs) and Serious AEs (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Severity (by Worst Grade) of Participants With Drug-related Adverse Events (AEs) and Serious AEs (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Visual Motor Integration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hand Skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Significant TR (moderate or severe)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of hyponatremia and hypernatremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Electrolyte outcomes
Primary endpoint: Brest cancer related lymphedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival Rate of Patients
Endpoint domain: Mortality/survival
Primary endpoint: Bleeding Rate of Patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Recurrent Incidence of Patients
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Circulating Cancer Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: surgical conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Development of complications of placental insufficiency
Endpoint domain: Adverse events/effects
Primary endpoint: Percent change in lumbar spine bone mineral density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: duration time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bicycle helmet use
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: BCVA - Better Seeing Eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: BCVA - Worse Seeing Eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: III4e Area - Better Seeing Eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: III4e Area - Worse Seeing Eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: V4e Area - Better Seeing Eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: V4e Area - Worse Seeing Eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Presence of dental caries on tooth occlusal surface
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hypoglycemia Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Dose-Limiting or Intolerable Treatment Related Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Median Change From Baseline in Platelets and White Blood Cell [WBC] Count (With Differentials) at Last Observation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Abnormal and Clinically Relevant Changes in Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of completed drug sensitivity testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients with excellent intubating conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Diagnosis of Crohn Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All cause recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Metabolic syndrome index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Level of Physical Activity/Sedentary Time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Level of Physical Activity/Low Activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Level of Physical Activity/Moderate-vigorous Activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: occurrence of a severe dementia (MMS < 10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: major depression detected by GDS-15 > 10/15 and confirmed by DSM-IV criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severe dependency (ADL < 3/6)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Scores on the Short Warwick-Edinburgh Mental Well-Being Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Total Recall Score in the Selective Reminding Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Score of the Alzheimer's Disease Assessment Scale-cognitive Subscale (ADAS-cog)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence and severity of adverse events (AE) and serious adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentages of participants discontinuing or suspending the study drug due to an AE
Endpoint domain: Adverse events/effects
Primary endpoint: Prevention of viral upper respiratory infections (URI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Participants not requiring drug dose reduction due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Validity of questionnaires to find pelvic floor symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day Uncomplicated Perineal Wound Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sensitivity of molecules in blood cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of molecules in blood cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection rates of Gallium 68-labeled PSMA-11 and fluciclovine F18
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in resting energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ability to use the paretic arm in activities of daily living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rey Auditory Verbal Learning Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Wechsler Memory Scale - Logical Memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Face-name associations test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Multifactorial Memory Questionnaire - Ability subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Decrease in the rate of late cancellation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Absolute Adhesional Abdominal Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Usability of phone calls
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Urinary excretion of total BIBR 953 ZW
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Peak (maximum) plasma concentration at steady state (Cmax,ss) of BIBR 953 ZW
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve at steady state (AUCss) of BIBR 953 ZW
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in myokine secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day Point-prevalence Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area Under the Concentration Versus Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)] for Colcrys™
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)] for Colcrys™
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Selenium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in soluble collagen content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction in skin hardness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Overall 12-month toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Percent CD8 HLA-DR+/CD38+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety of the CryoBalloon™ Ablation System
Endpoint domain: Adverse events/effects
Primary endpoint: NIRS value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak CI change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of PSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standardized uptake value of 68Ga-PSMA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 18F-labeled glucose uptake in muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Baseline Adjusted Mean Change in FEV1 AUC0-24h Post Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: change in total:HDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in fructosamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decrease in Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedure success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Engorgement Relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of instilled to prescribed drops
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deferred Imitation scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve (AUC0-infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Indoxyl Sulfate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Efficacy of Carbamazepine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FACES Pain Rating Scale Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pruritus incidence and intensity
Endpoint domain: Adverse events/effects
Primary endpoint: Area of flare induced by capsaicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Average itch post application of challenge agent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Physiologic Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Investigator Global Severity Scale (IGSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction in SCORing Atopic Dermatitis (SCORAD) Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction in Eczema Area and Severity Index (EASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in number of micturitions per 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of puncture(s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Potential biomarkers of sight-threatening eye diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete histological response proportion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breakpoint achieved for each stimulus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in breakpoints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: worst-ever bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Overall response rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Disease free period
Endpoint domain: Mortality/survival
Primary endpoint: complete response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: partial response (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of patients with abnormal findings in 12-lead ECG (electrocardiogram)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients with abnormal changes in laboratory tests (haematology, clinical chemistry and urinalysis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immediate DNA methylation profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of AKI
Endpoint domain: Adverse events/effects
Primary endpoint: Patient Global Severity Assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of severe RSV LRTI requiring hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Percent reduction in average monthly seizure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes of Systolic and Diastolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ECG Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Pruritis Visual Analog Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound Complications (Wound Dehiscence or Infection)
Endpoint domain: Adverse events/effects
Primary endpoint: Oxygen saturation nadir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection rate of pelvic metastatic disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Best Corrected Visual Acuity (BCVA) Gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Future Liver Remnant (FLR) Hypertrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Survival Rate at Month 6
Endpoint domain: Mortality/survival
Primary endpoint: Healing status at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pathologic complete remission rate (pCR rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Ventricular pacing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adhesion score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pain durance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Navigation Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of Major Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Wearing spectacles proportion
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of anticipatory nausea and vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of subjects whose RDAI symptom score increase by 2 or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in the mean capillary oxygen saturation change between groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Difference in the mean respiratory rate change between group
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of patients showing clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline seizures frequency 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline seizures frequency 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Occurrence of refractory epilepsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Knowledge about health literacy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Clinical attachment level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal velocity of performance (Vmax [deg/s])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of motion [deg] for slow stretch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feeding method at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunogenicity to influenza vaccine antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Weekly Frequency of Bowel Movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin Dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Brachial Artery Distensibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in lipid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in insulin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in testosterone concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Additional hemostatic measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of depressive disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall safety and tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Hamilton Anxiety Rating scale (HAM-A6) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of complete response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of partial response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of stable disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of progress disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in natriuretic peptide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Ki67 Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants That Experienced Change in Any Biomarker Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse event profiles
Endpoint domain: Adverse events/effects
Primary endpoint: maximal exercise times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in overall systematic error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in mean lung dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Radiological outcomes
Primary endpoint: Reduction in absolute pneumonitis risk
Endpoint domain: Adverse events/effects
Primary endpoint: IV access maintenance success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean Residual Peroxide at Day 30
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C reactive protein level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in HbA1c (Glycosylated Haemoglobin) (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number and severity of Dyskinesias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Safety and tolerability of AFQ056
Endpoint domain: Adverse events/effects
Primary endpoint: Composite endpoint of mortality, heart transplant, left ventricular assist device and readmission for decompensated heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of adolescent and youth who have transmissible HIV
Endpoint domain: Mortality/survival